Skip to main content
Mary Steinbach
( out of 66 reviews )

Mary Steinbach, APRN

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
801-585-2626
  • Mary Steinbach is a board-certified Nurse Practitioner for the Division of Hematology at the University of Utah Huntsman Cancer Institute, Blood and Marrow Transplant Program. She received her Bachelor of Science in Nursing from the University of Loyola Chicago and her Doctor of Nursing Practice degree from the University of Utah. Her early years as a registered nurse motivated her to advance her practice and she is proud to have worked as an NP at Huntsman for almost a decade. Mary’s clinical interests include hematology and more specifically caring for patients with Multiple Myeloma. She has served as a member of the International Myeloma Foundation’s Nurse Leadership Board (NLB) since 2018, working to improve the nurs­ing care and self-care of patients with myeloma. In her role on the NLB, Ms. Steinbach has made valuable contributions to the education of both patients and nurses through educational seminars across the country. Notably, Mary traveled to Abu Dhabi as part of the first stem cell transplant team in that country and she has contributed to several publications in reputable journals including Blood Advances, Seminars in Oncology Nursing, and Leukemia.

    Patient Rating

    5.0 /5
    ( out of 66 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 05, 2023
    HUNTSMAN CANCER CENTER

    She explained things very thoroughly and was good humored.

    July 30, 2023
    HUNTSMAN CANCER CENTER

    Mary is very kind and efficient.I like seeing Mary, a lot.

    July 25, 2023
    HUNTSMAN CANCER CENTER

    Mary is wonderful. She is an 11.

    July 22, 2023
    HUNTSMAN CANCER CENTER

    Mary is very approachable and caring.

    July 19, 2023
    HUNTSMAN CANCER CENTER

    Mary listened with respect and concern to help me find a solution to my problems.

    July 19, 2023
    HUNTSMAN CANCER CENTER

    Mary is a very smart, capable doctor. I appreciate her help.

    July 17, 2023
    HUNTSMAN CANCER CENTER

    Excellent

    July 16, 2023
    HUNTSMAN CANCER CENTER

    Always explains things very well and shows lots of care towards her patients.

    July 09, 2023
    HUNTSMAN CANCER CENTER

    Mary is terrific

  • Mary Steinbach is a board-certified Nurse Practitioner for the Division of Hematology at the University of Utah Huntsman Cancer Institute, Blood and Marrow Transplant Program. She received her Bachelor of Science in Nursing from the University of Loyola Chicago and her Doctor of Nursing Practice degree from the University of Utah. Her early years as a registered nurse motivated her to advance her practice and she is proud to have worked as an NP at Huntsman for almost a decade. Mary’s clinical interests include hematology and more specifically caring for patients with Multiple Myeloma. She has served as a member of the International Myeloma Foundation’s Nurse Leadership Board (NLB) since 2018, working to improve the nurs­ing care and self-care of patients with myeloma. In her role on the NLB, Ms. Steinbach has made valuable contributions to the education of both patients and nurses through educational seminars across the country. Notably, Mary traveled to Abu Dhabi as part of the first stem cell transplant team in that country and she has contributed to several publications in reputable journals including Blood Advances, Seminars in Oncology Nursing, and Leukemia.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Midlevel
    Academic Divisions Hematology

    Education history

    Doctoral Training Nursing - University of Utah DNP
    Nursing - Loyola University of Chicago BSN
    Undergraduate Environmental Geoscience - Boston College B.S.

    Selected Publications

    Journal Article

    1. Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic D (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv, 4(19), 4864-4868. (Read full article)
    2. Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D (2017). Elotuzumab as a novel anti-myeloma immunotherapy. Hum Vaccin Immunother, 13(8), 1751-1757. (Read full article)
    3. Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T (2016). Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology, 5(11), e1217374. (Read full article)
    4. Couriel DR, Ricker H, Steinbach M, Lee CJ (2016). Neurologic Manifestations of Blood Dyscrasias. Hematol Oncol Clin North Am, 30(4), 723-31. (Read full article)
    5. Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Krger N, Luetkens T, Atanackovic D (2015). CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother, 11(7), 1606-11. (Read full article)

    Review

    1. Hoshina Y, Galli J, Wong KH, Kovacsovics T, Steinbach M, Salzman KL, McNally JS, Lancaster E, Paz Soldn MM, Clardy SL (2022). GABA-A Receptor Encephalitis After Autologous Hematopoietic Stem Cell Transplant forMultiple Myeloma: Three Cases and Literature Review. [Review]. Neurol Neuroimmunol Neuroinflamm, 9(6). (Read full article)
    2. Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13, 20406207221100659. (Read full article)
    3. Steinbach M, Richards T, Faiman B (2017). Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. [Review]. Semin Oncol Nurs, 33(3), 254-264. (Read full article)

    Letter

    1. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. [Letter to the editor]. Leukemia, 34(1), 317-321. (Read full article)
    2. Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Krger N, Luetkens T, Atanackovic D (2015). Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. [Letter to the editor]. Blood Cancer J, 5, e285. (Read full article)
  • News & Podcasts

    Huntsman Cancer Institute News